Chandtip Chandhasin
Overview
Explore the profile of Chandtip Chandhasin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandhasin C, Dang V, Perabo F, Del Rosario J, Chen Y, Filvaroff E, et al.
Anticancer Drugs
. 2023 Apr;
34(10):1122-1131.
PMID: 37067993
Histone lysine demethylase 4 (KDM4) is an epigenetic regulator that facilitates the transition between transcriptionally silent and active chromatin states by catalyzing the removal of methyl groups on histones H3K9,...
2.
Sampson J, Singh Achrol A, Aghi M, Bankiewicz K, Bexon M, Brem S, et al.
Neuro Oncol
. 2023 Jan;
25(6):1085-1097.
PMID: 36640127
Background: MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is overexpressed in GBM as well as cells of the tumor...
3.
Antonarakis E, Chandhasin C, Osbourne E, Luo J, Sadar M, Perabo F
Oncologist
. 2016 Sep;
21(12):1427-1435.
PMID: 27628492
Implications For Practice: Because of emerging resistance mechanisms that involve the ligand-binding domain of the androgen receptor (AR), there is currently no effective treatment addressing tumor escape mechanisms related to...
4.
Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, et al.
Mol Cancer Ther
. 2011 Dec;
11(2):308-16.
PMID: 22203732
GRN1005 is a novel peptide-drug conjugate composed of paclitaxel covalently linked to a peptide, angiopep-2, that targets the low-density lipoprotein receptor-related protein 1. This first-in-human study evaluated the safety, tolerability,...
5.
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, et al.
Clin Cancer Res
. 2011 Jul;
17(18):6052-60.
PMID: 21750201
Purpose: Mammalian target of rapamycin (mTOR) inhibitors mediate AKT activation through a type 1 insulin-like growth factor receptor (IGF-1R)-dependent mechanism. Combining the mTOR inhibitor temsirolimus with cixutumumab, a fully human...
6.
Bolin L, Chandhasin C, Lobelle-Rich P, Albritton L, Levy L
Retrovirology
. 2011 May;
8:35.
PMID: 21569491
Background: Feline leukemia virus (FeLV)-945, a member of the FeLV-A subgroup, was previously isolated from a cohort of naturally infected cats. An unusual multicentric lymphoma of non-T-cell origin was observed...
7.
Naing A, Stephen S, Frenkel M, Chandhasin C, Hong D, Lei X, et al.
Cancer
. 2011 May;
117(22):5142-50.
PMID: 21538342
Background: A key end point of early cancer clinical trials is the assessment of toxicities and their possible association with new experimental drugs. Therefore, the concurrent use of complementary and...
8.
Tsimberidou A, Chandhasin C, Kurzrock R
Expert Opin Investig Drugs
. 2010 Nov;
19(12):1569-80.
PMID: 21083522
Importance Of The Field: Farnesyltransferase inhibitors (FTIs) target multiple pathways implicated in the pathogenesis of solid and hematologic malignancies. Areas Covered In This Review: Novel preclinical and clinical data on...
9.
Chandhasin C, Ducu R, Berkovich E, Kastan M, Marriott S
J Virol
. 2008 Apr;
82(14):6952-61.
PMID: 18434398
Genomic instability, a hallmark of leukemic cells, is associated with malfunctioning cellular responses to DNA damage caused by defective cell cycle checkpoints and/or DNA repair. Adult T-cell leukemia, which can...
10.
Chandhasin C, Coan P, Pandrea I, Grant C, Lobelle-Rich P, Puetter A, et al.
J Virol
. 2005 Apr;
79(9):5278-87.
PMID: 15827142
The outcome of feline leukemia virus (FeLV) infection in nature is variable, including malignant, proliferative, and degenerative disorders. The determinants of disease outcome are not well understood but are thought...